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Summan A late phase I1 study of a new camptothecin analogue. inrnotecan hydrochloride (CPT-l1). was
conducted to evaluate the anti-tumour effect and toxicity in patients with refractory leukaemia and lymphoma
including adult T-cell leukaemia (ATL)-lymphoma. in a multi-institutional cooperative study. All the patients
with ATL had been previously treated with various conventional combination chemotherapies and were
refractonr to these therapies or had relapsed. CPT- 1 1 was administered at a dose of 40 mg m- day -' for three
consecutive days repeated weekly until eVidence of disease progression. One complete remission and four
partial remissions were achieved in 13 assessable patients with ATL. The median total dose to achieve
remission was 240 mg m and the median duration of response was 31 days. The major toxicities were
leucopenia (83%). diarrhoea (62%) and nausea vomiting (69%). These were relatively severe. but they were
generally tolerable and reversible. However. one patient died probably as a result of this therapy. No effective
chemotherapy for adult T-cell leukaemia-lymphoma has yet been established, and the prognosis for patients
with this disease is very poor. Our results suggest that CPT-l1 may be a promising agent for this disease.
Further combination therapy with CPT-11 is needed to improve the therapy for ATL.
The prognosis of adult T-cell leukaemia-lymphoma (ATL) is
generally very poor (Shimoyama et al., 1988a. 1991). and the
median survival times (MSTs) for the acute, lymphoma and
chronic types are 5.4, 10.2 and 24.3 months respectively
(Shimoyama et al., 1991). Chemotherapy for ATL has been
largely unsuccessful because of tumour resistance, and it was
recently reported that ATL cells frequently express the
MDR-1 gene product. a membrane P-glycoprotein., at the
time of presentation (Kuwazuru et al., 1990). Thus. a new
agent having a different mechanism of action is needed, and
activity in models of multidrug resistance may be rele-
vant.
Irinotecan hydrochlonrde (CPT- ll) is a semisynthetic and
water-soluble derivative of camptothecin, an anti-tumour
alkaloid isolated from Camptotheca acuminata (Wall et al..
1966). This compound has displayed excellent in vitro and in
vivo anti-tumour activity in a variety of preclinical studies
(Kunimoto et al.. 1987: Bissery et al.. 1991). CPT-l acts
through the inhibition of topoisomerase I (Kawato et al..
1991: Andoh. 1992). CPT-11 is reported to be effective
against vincristine- and doxorubicin-resistant P388 leukaemia
both in vitro and in vivo (Tsuruo et al.. 1988), suggesting that
it may be able to overcome multidrug resistance.
A late phase II study of CPT- 11 was conducted in Japan
to evaluate its anti-tumour effects and toxicity in patients
with various types of leukaemia and lymphoma, including
ATL (Tsuda et al.. 1992). In the present report, the results
were analysed with the focus on ATL, in order to determine
whether CPT-I1 has any worthwhile activity against ATL.
Patients and methods
Patients
Patients were enrolled in this study if they fulfilled the
following eligibility criteria: (1) histologically confirmed
leukaemia or malignant lymphoma. (2) measurable and evalu-
able disease. (3) refractory to standard therapy. (4) no
radiotherapy or chemotherapy within 2 weeks before entry,
(5) life expectancy of at least 2 months. (6) performance
status of 3 or better according to the Eastern Cooperative
Oncology Group (ECOG). (7) adequate bone marrow. lung.
liver, and renal function. (8) no serious complications. (9) no
other active malignancies. (10) a negative reaction to skin test
for CPT-11. Informed consent was obtained from all patients
before entry. ATL was diagnosed and classified according to
the criteria of the Ly'mphoma Study Group (Shimoyama et
al.. 1991).
Study design
This was an open, non-randomized phase II study in patients
with refractory or relapsed leukaemia and lymphoma that
was designed to evaluate the anti-tumour effect and toxicity
of CPT- 1. A complete blood count and biochemistry tests
were routinely done. Response was judged by the Japan
Society for Cancer Therapy in accordance with the criteria of
the World Health Organization (World Health Organization.
1979). The eligibility. suitability and handling of each patient
were determined by an evaluation committee. The study was
approved by the ethics committee of each participating insti-
tution.
Treatment schedule
Based on the results of an early phase II study. 40 mg m`
CPT-l was administered as a 60 min intravenous infusion
on three consecutive days per week repeated every week until
disease progression or intolerable toxicity occurred. When
myelosuppression and diarrhoea occurred, administration
was postponed until their recovery.
Results
Patients' background
Patients with relapsed or refractory leukaemiia and lymphoma
were enrolled into this study from 34 Japanese institutions
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Table I Clinmcal charactenrstics of the ATL patients
Patient Age No. of LDHI Cad No. of Disease
no. Sex (Years) PS' Tipe ofATL Disease sites sites (ILt ') (mgdl-') previous agents status
2 M 63 2 Lymphoma Abdominal LNd 2 1,413 10.8 8 PrRe
tonsil
5 M 61 1 Lymphoma Mediastinal LN 1 608 8.8 12 PrR
6 M 44 1 Lymphoma Superficial LN 1 1,020 7.9 9 RRf
8 F 74 1 Lymphoma Superficial LN 1 407 9.7 1 PrR
12 M 66 0 Lymphoma Superficial LN 2 726 8.8 9 Rt
lung
Mean 61.8 1 - 1.2 835 9.2 7.8
I F 70 3 Lymphoma Abdominal LN 2 2,943 13.4 6 PrR
Tonsil
3 F 78 2 Acute Penrpheral blood 2 822 10.6 7 PrR
Spleen
4 F 67 3 Lymphoma Superficial LN 1 935 8.7 3 RR
7 M 49 2 Lymphoma Superficial LN 1 1,635 8.9 6 R
9 F 60 3 Acute Peripheral blood 1 888 8.9 4 PrR
10 M 59 3 Lymphoma Abdominal LN 3 735 11.8 16 RR
Superficial LN
Pleural fluid




14 M 50 2 Lymphoma Superficial LN 1 666 8.6 4 RR
Mean 63.1 2.6 1.9 1,279 10.0 6.5
'PS performance status. bNormal range 200-450 IU 1-'. 'Normal range 8.5-10.2 mgdl-'.dLN. lymph node. 'PrR, primary refractory. fR.
relapsed. ERR. relapsed and retractory.
Table 11 Response and administration
Patient Total dose Time to CR, PR Dose to CR, PR Duration of
no. Response (mg m2) (days) (mgm2) response (dayIs)
Responder 2 PR 680 13 240 39
5 CR 3.585 13 240 130
6 PR 600 24 360 31
8 PR 236 6 117 29
12 PR 540 12 120 29
Median - 600 13 240 31
Non-responder I NC 330 - - -
3 PD 240 - - -
4 NC 480 - - -
7 PD 760 - - -
9 NC 500 - - -
10 PD 410 - - -
11 PD 160 - - -
14 PD 360 - - -
Median - 385 -
Total median 480
between February 1990 and March 1992. Seventy-nine
patients were registered, including 14 patients with ATL from
five institutions. Thirteen of 14 ATL patients were assessable
for efficacy and toxicity (Table I). One patient (no. 13) was
excluded from evaluation because of short interval of prior
therapy before starting CPT-11. All patients had been treated
previously with various conventional combination chemo-
therapies. Seven patients were refractory to the initial induc-
tion therapy, two had relapsed after achieving CR with the
prior chemotherapy and four were relapsed and refractory to
second or subsequent induction chemotherapy regimens.
Response
Among the 13 patients evaluated, one achieved CR and four
achieved PR (Table II). The CR was obtained in patient
no. 5, who had lymphoma type of ATL with massive media-
stinal lymphadenopathy. The disease had been resistant to
various prior forms of chemotherapy. CR was achieved after
the second course of CPT-11, and it lasted for 130 days. All
the PR patients also had lymphoma-type ATL and had
received various forms of chemotherapy. PR was achieved at
13, 24, 6 and 12 days after the start of CPT-l1 therapy and
lasted for 39, 31, 29 and 29 days respectively. The median
time to PR (including the CR patient) was 13 days and the
median duration of PR was 31 days. The time course of the
change in tumour size for each responder is outlined in
Figure 1. A reduction in tumour size was apparent after only
1 week of treatment in four out of five patients. Complete
disappearance of measurable lesions actually occurred in two
patients (no. 5 and 12) after two and three courses of treat-
ment respectively. However, patient no. 12 was not judged as
having achieved CR because a radiologically visible but
unmeasurable pulmonary deposit did not disappear com-
pletely after the treatment. The serum lactic acid dehydro-
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Figure 1 The time course of the change in tumour size in
CPT- 11 responders. The size of tumours was measured as
indicated by the Japan Society for Cancer Therapy in accordance
with the criteria of the World Health Organization. Each point
represents the tumour size relative to that just before CPT-I1
therapy. 0. Patient 2: 0. patient 5: <l. patient 6: 0. patient 8: M.
patient 12.
before treatment were 835 ± 392 and 1.279 ± 770 IU 1-'
(mean ± s.d.) respectively. The decrease in LDH levels of
responders was 12-62% compared with pretreatment levels 2
weeks after the start of therapy (data not shown). The lower
LDH level persisted for 8 weeks except in one patient whose
LDH level remained moderately elevated.
Toxicity
The toxicities caused by CPT-II therapy are listed in Table
III. Myelosuppression was the most common toxicity
observed: leucopenia was noted in 83%, anaemia in 67% and
thrombocytopenia in 50%. Toxicity was generaly reversible,
2-3 weeks were required for recovery to the pretreatment
level. Nausea and vomiting occurred in 69% and diarrhoea
in 62%. All patients who experienced diarrhoea recovered.
The median day of recovery from onset of diarrhoea was 4
days (range 1-34). Mild elevation of the level of glutamic
oxaloacetic transaminase (GOT) and/or glutamic pyruvic
transaminase (GPT) was seen in 15%. In addition, alopecia
developed in 40%, but haemorrhagic cystitis was not
observed. However, one patient (no. 4) died probably as a
result of treatment for aspiration pneumonia caused by
leucopenia.
The prognosis of adult patients with advanced peripheral
T-cell lymphoma-leukaemia is generally poor, and ATL is
the worst among this group of diseases (Shimoyama et al.,
1988a). Patients with ATL have been treated by various
agents and schedules, such as VEPA (Shimoyama et al.,
1988b), CHOP (McKelvey et al.. 1976) and MACOP-B
(Klimo et al.. 1985). In addition, treatment with etoposide,
interferon-a and interferon-y as single agents has been tried,
but the survival benefit of any of these regimens remains
uncertain (Shimoyama et al.. 1988a). The MDR-1 gene or
P-glycoprotein seems to be involved in the development of
drug resistance in various tumours including ATL (Marie et
al., 1991; Campos et al., 1992; Haber. 1992). Thus, more
effective agents and treatments for ATL are required.
The anti-tumour activity of CPT-I 1 is attributed to inhibi-
tion of topoisomerase I (Kawato et al., 1991; Andoh, 1992).
In addition, it has been shown that there is no cross-
resistance between CPT-1 1 and adriamycin or vincristine
both in animal tumour models and in vitro studies (Tsuruo et
al.. 1988). Phase II trials in various tumour types, including
lung (Fukuoka et al., 1992a, b), ovary, cervical (Umesaki,
1992), colorectal cancer (Shimada et al., 1993) and haemato-
logical malignancies (Ohno et al.. 1990). have been performed
in Japan. and CPT-I 1 showed definite clinical response. The
response rate of ATL patients in our study was 38% (5 13).
The duration of response in our study was short. but our
data do suggest a wide anti-tumour spectrum for CPT- 11.
This promising drug may be able to overcome multiple drug
resistance related to the MDR-1 gene or P-glycoprotein in
tumours such as ATL. but this at present remains specula-
tive.
The major side-effects were myelosuppression and gastro-
intestinal toxicities. Leucopenia was more severe than throm-
bocytopenia. as was observed in previous clinical studies.
Diarrhoea was also severe, but reversible. It could generally
be minimised by a standard dose of an anticholinergic agent.
Treatment sometimes had to be postponed owing to leuco-
penia and diarrhoea, but in general treatment was repeated
as planned. However. one patient died as a result of this
treatment. The patient experienced grade 3 leucopenia and
diarrhoea and a deterioration in general condition which
caused an aspiration pneumonia. Thus, in regard to these
side-effects, special care must be taken and adequate suppor-
tive therapy is needed.
According to a recent large-scale study, five factors are
associated with a reduced survival in ATL, including poor
performance status, high LDH level, age >40 years. a
greater number of lesions and hypercalcaemia (Lymphoma
Study Group, 1991). All patients enrolled in our study
received various previous forms of chemotherapy and had
several adverse prognostic factors (Table I). This suggests
that more satisfactory results may be achievable in untreated
patients with better performance status.
In conclusion, our results show that CPT-l is clinically
effective against ATL. Some cell lines resistant to CPT-ll
have recently been established and have altered forms of
Table III Major toxicities
No. ofevaluable Grade
Toxicitv patients 1 2 3 4 %
Leucopenia 12 0 2 4 4 83
Anaemia 12 2 2 3 1 67
Thromboc topenia 12 1 0 4 1 50
Elevation of GOT GPT 13 1 1 0 0 15
Elesation of total bilirubin 13 0 0 0 0 0
Elevation of BUN 13 0 0 0 0 0
Diarrhoea 13 1 1 6 0 62
Nausea vomiting 13 4 2 3 - 69
Alopecia 10 0 2 2 - 40774 H. TSUDA et al.
topoisomerase I. suggesting one possible form of clinical
resistance to CPT-l 1 (Kawato et al.. 1991; Andoh. 1992). An
enhanced anti-tumour activity of CPT-11 in combination
with other anticancer agents has been demonstrated both in
vitro and in clinical studies (Kano et al.. 1992; Masuda et al..
1993). Accordingly. CPT-I I may be more effective when
utilised in combination with other agents which have a
different mode of action and different resistance
mechanisms.
The following doctors were also participants in this study: Dr
Kuniyuki Imai, Tokyo Metropolitan Komagome Hospital. Tokyo.
Dr Shiro Fukuhara. Kyoto University. Kyoto: Dr Shuichi Hanada.
Kagoshima University. Kagoshima.
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